- Report
- January 2025
- 250 Pages
Global
From €4546EUR$4,999USD£3,908GBP
- Report
- May 2024
- 131 Pages
Global
From €2727EUR$2,999USD£2,345GBP
€3636EUR$3,999USD£3,126GBP
- Report
- May 2024
- 138 Pages
Global
From €2727EUR$2,999USD£2,345GBP
€3636EUR$3,999USD£3,126GBP
- Report
- November 2024
- 39 Pages
Global
From €3633EUR$3,995USD£3,123GBP
- Report
- August 2025
- 169 Pages
Global
From €16363EUR$17,995USD£14,068GBP
- Report
- May 2018
- 127 Pages
Global
From €13635EUR$14,995USD£11,723GBP
- Report
- November 2023
- 150 Pages
Global
From €4410EUR$4,850USD£3,792GBP
- Report
- July 2025
- 134 Pages
Global
From €4228EUR$4,650USD£3,635GBP
- Report
- May 2025
- 130 Pages
Global
From €4410EUR$4,850USD£3,792GBP
- Drug Pipelines
- July 2023
- 139 Pages
Global
From €13635EUR$14,995USD£11,723GBP
- Report
- June 2018
- 16 Pages
Global
From €9093EUR$10,000USD£7,818GBP
- Report
- February 2024
- 86 Pages
Global
From €3500EUR$4,123USD£3,114GBP
Levodopa is a drug used to treat Parkinson's disease, a neurological disorder that affects movement. It is a dopamine precursor, meaning it is converted into dopamine in the brain, which helps to reduce the symptoms of Parkinson's. Levodopa is usually taken in combination with other drugs, such as carbidopa, to increase its effectiveness. It is one of the most commonly prescribed drugs for Parkinson's, and is often the first line of treatment.
Levodopa is a part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological disorders. The CNS drug market is highly competitive, with many different companies offering various treatments.
Some of the companies in the Levodopa market include Merck, Novartis, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more
